Quick Answer
UNITED THERAPEUTICS Corp reported Research And Development Expense of $550.00 million for the year ending 2025.
- UNITED THERAPEUTICS Corp showed an increase of +14.3% in Research And Development Expense from 2024 to 2025.
- This data is from UNITED THERAPEUTICS Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), UNITED THERAPEUTICS Corp's Research And Development Expense has grown by 130.0%.
- Historical annual values: Fiscal year 2025: $550.00 million | Fiscal year 2024: $481.00 million | Fiscal year 2023: $408.00 million | Fiscal year 2022: $322.90 million | Fiscal year 2021: $540.10 million | Fiscal year 2020: $357.70 million | Fiscal year 2019: $1.18 billion | Fiscal year 2018: $357.90 million | Fiscal year 2017: $264.60 million | Fiscal year 2016: $147.60 million | Fiscal year 2015: $245.10 million | Fiscal year 2014: $242.50 million | Fiscal year 2013: $299.35 million | Fiscal year 2012: $173.39 million | Fiscal year 2011: $180.02 million | Fiscal year 2010: $165.31 million | Fiscal year 2009: $120.37 million | Fiscal year 2008: $239.18 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: